Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Expérience confirmée
20 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté
20ans d'exercice (thèse 2006)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
21
21 articles ont été cités au moins 21fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 621
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
85
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
32
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Empirical antibiotic therapy modalities for Enterobacteriaceae bloodstream infections in older patients and their impact on mortality: a multicentre retrospective study
2023ArticleInfection
How to improve the quality of the care of elderly subjects in nursing homes nowadays? Ger-e-Tech, a telemonitoring project dedicated to nursing homes
2019CongrèsJournées d'Etude sur la TéléSanté
Induction de tolérance par les cellules dendritiques : prévention du diabète par le transfert des cellules dendritiques chez la souris Non Obese Diabetic
2006Thèse
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL SAINT JULIEN CHU ROUEN
2 R DANTON BP 201, 76141 LE PETIT QUEVILLY CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Cellular & molecular immunology · 2023
AbstractGraft versus host disease (GvHD) is the clinical condition in which bone marrow-derived mesenchymal stromal cells (MSCs) have been most frequently studied. In this review, we summarize the experience from clinical trials that have paved the way to translation. While MSC-based therapy has shown an exceptional safety profile, identifying potency assays and disease biomarkers that reliably predict the capacity of a specific MSC batch to alleviate GvHD has been difficult. As GvHD diagnosis and staging are based solely on clinical criteria, individual patients recruited in the same clinical trial may have vastly different underlying biology, obscuring trial outcomes and making it difficult to determine the benefit of MSCs in subgroups of patients. An accumulating body of evidence indicates the importance of considering not only the cell product but also patient-specific biomarkers and/or immune characteristics in determining MSC responsiveness. A mode of action where intravascular MSC destruction is followed by monocyte-efferocytosis-mediated skewing of the immune repertoire in a permissive inflammatory environment would both explain why cell engraftment is irrelevant for MSC efficacy and stress the importance of biologic differences between responding and nonresponding patients. We recommend a combined analysis of clinical outcomes and both biomarkers of disease activity and MSC potency assays to identify patients with GvHD who are likely to benefit from MSC therapy.
Stem cells translational medicine · 2020
Abstract Steroid-refractory chronic graft-vs-host disease (cGvHD) contributes to morbidity after allogeneic hematopoietic stem cell transplantation. Here, we report on 11 patients with severe, refractory cGvHD treated with repeated infusions of allogeneic bone marrow-derived mesenchymal stromal cells (MSC) over a 6- to 12-month period. Six patients responded to MSC treatment following National Institutes of Health response criteria, accompanied by improvement in GvHD-related symptoms and quality of life. This response was durable, with systemic immunosuppressive therapy withdrawn from two responders, and a further two free from steroids and tapering calcineurin inhibitors. All responders displayed a distinct immune phenotype characterized by higher levels of naïve T cells and B cells before treatment compared with the nonresponders, and a significantly higher fraction of CD31+ naïve CD4+ T cells. MSC treatment was associated with significant increases in naïve T cells, B cells, and Tregs 7 days after each infusion. Skin biopsies showed resolution of epidermal pathology. CXCL9 and CXCL10 showed differential responses in responder and nonresponder patients. Our data support the use of MSC infusions as treatment for steroid-refractory cGvHD with durable responses. We propose CXCL9 and CXCL10 as early biomarkers for responsiveness to MSC treatment. Our results highlight the importance of the MSC recipient immune phenotype in promoting treatment response. This trial was registered at www.ClinicalTrials.gov as #NCT01522716.
Immunology and cell biology · 2018
AbstractMultiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system involving dysregulated encephalitogenic T cells. Myeloid‐derived suppressor cells (MDSCs) have been recognized for their important function in regulating T‐cell responses. Recent studies have indicated a role for MDSCs in autoimmune diseases, but their significance in MS is not clear. Here, we assessed the frequencies of CD14+HLA‐DRlow monocytic MDSCs (Mo‐MDSCs) and CD33+CD15+CD11b+HLA‐DRlow granulocytic MDSCs (Gr‐MDSCs) and investigated phenotypic and functional differences of Mo‐MDSCs at different clinical stages of MS and in healthy subjects (HC). Increased frequencies of Mo‐MDSCs (P < 0.05) and Gr‐MDSCs (P < 0.05) were observed in relapsing‐remitting MS patients during relapse (RRMS‐relapse) compared to stable RRMS (RRMS‐rem). Secondary progressive MS (SPMS) patients displayed a decreased frequency of Mo‐MDSCs and Gr‐MDSCs compared to HC (P < 0.05). Mo‐MDSCs within RRMS patients expressed significantly higher cell surface protein levels of CD86 and CD163 compared to SPMS patients. Mo‐MDSCs within SPMS exhibited decreased mRNA expression of interleukin‐10 and heme oxygenase 1 compared to RRMS and HC. Analysis of T‐cell regulatory function of Mo‐MDSCs demonstrated T‐cell suppressive capacity in RRMS and HCs, while Mo‐MDSCs of SPMS promoted autologous T‐cell proliferation, which aligned with a differential cytokine profile compared to RRMS and HCs. This study is the first to show phenotypic and functional shifts of MDSCs between clinical stages of MS, suggesting a role for MDSCs as a therapeutic target to prevent MS disease progression.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Cytotherapy · 2025 · Journal Article
Blanc KL, Dazzi F, English K, Farge D, et al.
Cellular & molecular immunology · 2023 · Journal Article
Kadri N, Amu S, Iacobaeus E, Boberg E, et al.
Frontiers in cellular neuroscience · 2022 · Editorial
Capilla-González V, Herranz-Pérez V, Sarabia-Estrada R, Kadri N, et al.
Journal of clinical medicine · 2019 · Journal Article
Iacobaeus E, Kadri N, Lefsihane K, Boberg E, et al.
Immunology and cell biology · 2018 · Journal Article
Iacobaeus E, Douagi I, Jitschin R, Marcusson-Ståhl M, et al.
Soins. Gerontologie · 2017 · Journal Article
Majot M, Kadri N, Doucet J, Zulfiqar AA
Transfusion · 2016 · Journal Article
Meinke S, Sandgren P, Mörtberg A, Karlström C, et al.
Revue de l'infirmiere · 2018 · Journal Article
Zulfiqar AA, Doucet J, Kadri N
Geriatrie et psychologie neuropsychiatrie du vieillissement · 2018 · Journal Article
Zulfiqar AA, Blazejczyk P, Kadri N, Doucet J
Soins. Gerontologie · 2017 · Journal Article
Zulfiqar AA, Sui Seng X, Duhamel E, Kadri N, et al.
European journal of internal medicine · 2017 · Letter
Zulfiqar AA, Sui Seng X, Gillibert A, Kadri N, et al.
Stem cells translational medicine · 2020 · Clinical Trial, Phase II
Boberg E, von Bahr L, Afram G, Lindström C, et al.
La Tunisie medicale · 2025 · Case Reports
Mrad S, Thabet M, Kadri N, Guiga A, et al.
Soins. Gerontologie · 2017 · Case Reports
Zulfiqar AA, Fouqué A, Sui Seng X, Kadri N, et al.
Stem cell research & therapy · 2026 · Journal Article
Bergström Börlin E, Nygren U, Södersten M, Granqvist S, et al.
Stem cell research & therapy · 2026 · Journal Article
Bergström Börlin E, Nygren U, Södersten M, Granqvist S, et al.
European journal of case reports in internal medicine · 2019 · Case Reports
Bensiradj F, Hignard M, Nakkash R, Proux A, et al.
An open phase I/IIa study evaluating safety, patient-reported outcomes and voice function after surgery, local administration of mesenchymal stromal cells and voice training in patients with vocal fold scarring and dysphonia
Abstract Background Damage to the vocal folds can result in scarring, leading to chronic, severe voice impairments for which lasting and effective treatments are currently lacking. The aim of this clinical trial was to e
L'évaluation de la fragilité par le médecin généraliste : étude comparative à une évaluation gériatrique menée chez 55 personnes âgées résidant sur 3 RPA de Seine-Maritime
INTERET DES THERAPIES PAR L’ART ET DES AUTRES THERAPIES NON MEDICAMENTEUSES DANS LA PRISE EN CHARGE DU PATIENT ATTEINT DE LA MALADIE D’ALZHEIMER
An open phase I/IIa study evaluating safety, patient-reported outcomes and voice function after surgery, local administration of mesenchymal stromal cells and voice training in patients with vocal fold scarring and dysphonia
Abstract Background Damage to the vocal folds can result in scarring, leading to chronic, severe voice impairments for which lasting and effective treatments are currently lacking. The aim of this clinical trial was to e
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Fundamental & clinical pharmacology · 2012 · Comparative Study
Cadiou G, Adam M, Caussin M, Landrin I, et al.
Presse medicale (Paris, France : 1983) · 2005 · English Abstract
Chassagne P, Druesne L, Bentot C, Kadri N